98%
921
2 minutes
20
This study investigated the behavioral effects of intravenous caffeine administration in mice using a modified Irwin test. Thirty-two male ICR mice were divided into four groups and received intravenous doses of caffeine: 0 (control), 5, 10, or 20 mg/kg. Behavioral observations were conducted at 0, 0.25, 1.5, 6, and 24 h post administration. Notable traction, locomotion, and respiratory rate changes were observed at 10 and 20 mg/kg doses. Specifically, traction was altered at 0.25 and 1.5 h in the 10 mg/kg group, with more frequent alterations in the 20 mg/kg group. Increased locomotion (grade 6, characterized by frequent grooming and rapid movement) was observed in all the mice at 10 and 20 mg/kg doses between 0.25 and 1.5 h. Respiratory rate changes were observed only in the 20 mg/kg group during the same period. Our findings indicate that intravenous caffeine exposure significantly affects traction and locomotion, providing valuable insights for safe pharmacological testing of the central nervous system.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3177/jnsv.71.267 | DOI Listing |
Eur J Med Chem
August 2025
School of Chemistry and Chemical Engineering, Anhui University of Technology, Ma'anshan, 243032, Anhui, PR China. Electronic address:
Cancer remains a leading global cause of mortality, with treatment efficacy often compromised by drug resistance, highlighting the urgent need for novel targeted therapies. The enzyme fructose-2,6-bisphosphatase 4 (PFKFB4) governs glycolytic flux by modulating fructose-2,6-bisphosphate (F2,6BP) levels. PFKFB4 overexpression has been observed in various cancers and correlates with tumor growth, aggressiveness, and poor prognosis.
View Article and Find Full Text PDFBlood
September 2025
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
Isatuximab is an IgG1k monoclonal antibody that binds with high affinity to CD38 expressed on plasma cells. Anti-CD38 antibodies have shown efficacy as monotherapy and in combination in a variety of settings for patients with multiple myeloma and light chain (AL) amyloidosis. This multi-center, cooperative group phase 2 trial was designed to evaluate hematologic response, organ response, and safety of isatuximab monotherapy for the treatment of relapsed AL amyloidosis.
View Article and Find Full Text PDFMol Pharm
September 2025
Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Tissue factor (TF) has emerged as a promising target for the diagnosis and treatment of hepatocellular carcinoma (HCC). However, there is limited data available on TF-related PET imaging for longitudinal monitoring of the pathophysiological changes during HCC formation. Herein, we aimed to explore the TF-expression feature and compare a novel TF-targeted PET probe with F-FDG through longitudinal imaging in diethylnitrosamine (DEN)-induced rat HCC.
View Article and Find Full Text PDFJ Drug Target
September 2025
Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Background: Chronic constriction injury (CCI) of the sciatic nerve induces neuropathic pain, inflammation, oxidative stress, and neurodegenerative changes, impairing sensory and emotional function. While curcumin is well recognized for its anti-inflammatory and neuroprotective properties, its therapeutic use is limited by poor bioavailability. Curcumin liposomal nanoparticles (CLNs) offer improved delivery and stability.
View Article and Find Full Text PDFEur Arch Paediatr Dent
September 2025
Araçatuba School of Dentistry, São Paulo State University - UNESP, Araçatuba, Brazil.
Purpose: This systematic review provides a critical evaluation, synthesis of the existing literature on isotretinoin's effects on craniomaxillofacial bone.
Methods: Following the PRISMA guidelines and registered in PROSPERO, the review was conducted in August 2024 across various databases. Eligible in vivo studies were analysed for their assessment of isotretinoin's effects on craniomaxillofacial bone.